Eraxis

• Anti-HIV Agents
• HIV Protease Inhibitors
• ATC:J05AE09

• Eraxis

• No information avaliable

C₃₄H₃₆N₂O₅S

No information avaliable

Eraxis FDA

Eraxis MSDS

No information avaliable

584.726 g/mol

No information avaliable

Insoluble

Solid

8.369

Capsules (250 mg)

For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.

Tipranavir is a non-peptidic protease inhibitor (PI) of HIV. Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

Absorption is limited, although no absolute quantification of absorption is available.

Oral LD₅₀ in rat is over 5,000 mg/kg. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.

No information avaliable

Human immunodeficiency virus